Cancer treatment-induced bone loss: Pathophysiology and clinical perspectives

Oncologist

Volumn 13, Issue 2, 2008, Pages 187-195

  Brufsky, Adam M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Androgen deprivation therapy; Aromatase inhibitor; Bisphosphonate; Bone loss; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EXEMESTANE; FLUOROURACIL; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HOT FLUSH; HUMAN; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 40349093042     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0152     Document Type: Review

References (64)

1. Diamond TH, Higano CS, Smith MR et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 2004;100:892-899.
2. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005;32:589-603.
3. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 2000;18:1570-1593.
4. Hofbauer LC, Khosla S. Androgen effects on bone metabolism: Recent progress and controversies. Eur J Endocrinol 1999;140:271-286.
5. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
6. Saad F, Higano CS, Sartor O et al. The role of bisphosphonates in the treatment of prostate cancer: Recommendations from an expert panel. Clin Genitourin Cancer 2006;4:257-262.
7. Kanis JA, Oden A, Johnell O et al. The components of excess mortality after hip fracture. Bone 2003;32:468-473.
8. Mincey BA. Osteoporosis in women with breast cancer. Curr Oncol Rep 2003;5:53-57.
9. Saarto T, Blomqvist C, Valimaki M et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-1347.
10. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306 -3311.
11. Vehmanen L, Saarto T, Elomaa I et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373-2378.
12. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
13. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-1223.
14. Eastell R, Adams J. Results of the 'Arimidex' (anastrozole, A), Tamoxifen (T), Alone or in Combination (C) (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group). Presented at the 27th Congress of the European Society for Medical Oncology, Nice, France, October 18-22, 2002.
15. Bell R. Relative risk of fractures in postmenopausal women, postmenopausal breast cancer survivors and postmenopausal women managed with adjuvant hormonal therapy. Presented at the 5th European Breast Cancer Conference, Nice, France, March 21-25, 2006.
16. Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006;7:127-132.
17. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-828.
18. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. 17. J Clin Oncol 2006;24:3629 -3635.
19. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007;8:119-127.
20. Gonnelli S, Cadirni A, Caffarelli C et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007;40:205-210.
21. Lonning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-5137.
22. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006;42:1044-1051.
23. Leder BZ, LeBlanc KM, Schoenfeld DA et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003;88:204-210.
24. Hussain SA, Weston R, Stephenson RN et al. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003;92:690-694.
25. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222.
26. Mittan D, Lee S, Miller E et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-3661.
27. Kanis JA, Melton LJ 3rd, Christiansen C et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
28. Krupski TL, Smith MR, Lee WC et al. Profile of men with prostate cancer on androgen deprivation therapy at greatest risk of bone complications. Proc Am Soc Clin Oncol 2004;22(July 15 suppl):726.
29. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
30. Smith MR, Lee WC, Krupsi T et al. Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer. Proc Am Soc Clin Oncol 2004;22(July 15 suppl):382.
31. Lopez AM, Pena MA, Hernandez R et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005;16:707-711.
32. Bruder JM, Ma JZ, Basler JW et al. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006;67:152-155.
33. Oefelein MG, Ricchiuti V, Conrad W et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
34. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
35. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study. Osteoporos Int 2002;13:257-264.
36. Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc 2000;75:821-829.
37. Hortobagyi GN. Moving into the future: Treatment of bone metastases and beyond. Cancer Treat Rev 2005;31(suppl 3):S9-S18.
38. Lipton A. Toward new horizons: The future of bisphosphonate therapy. The Oncologist 2004;9(suppl 4):38-47.
39. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-962.
40. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
41. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
42. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882.
43. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
44. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474.
45. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-836.
46. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast 2006;15(suppl 1):S30 -S40.
47. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer V. 2.2007. Jenkintown, PA: NCCN, 2007:1-48.
48. Lam RY, Scholz M, Guess B et al. Oral bisphosphonates fail to prevent bone loss from androgen deprivation therapy in men with prostate cancer. Presented at the 2006 ASCO Prostate Cancer Symposium, San Francisco, CA, February 24-26, 2006.
49. Greenspan SL, Nelson JB, Trump DL et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 2007;146:416-424.
50. Boniva® (ibandronate sodium) tablets [package insert]. Nutley, NJ: Roche, 2006.
51. Mangiapane S, Hoer A, Gothe H et al. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 2006;24(June 20 suppl):698s.
52. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012.
53. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
54. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
55. Michaelson MD, Lee H, Kaufman DS et al. Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial. J Clin Oncol 2006;24(June 20 suppl):220s.
56. Casey R. Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin: 12-month results. Presented at The Prostate Cancer Symposium, Orlando, FL, February 22-24, 2007.
57. Carroll PR. Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S, et al, eds. Prostate Cancer: 3rd International Consultation on Prostate Cancer. Paris: Health Publications, 2003:249-284.
58. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004;9(suppl 4):28-37.
59. Sehbai AS, Mirza MA, Ericson SG et al. Osteonecrosis of the jaw associated with bisphosphonate therapy: Tips for the practicing oncologist. Commun Oncol 2007;4:w1-w11.
60. Weitzman R, Sauter N, Eriksen EF et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007;62:148-152.
61. Mavrokokki T, Cheng A, Stein B et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423.
62. Marx RE, Sawatari Y, Fortin M et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
63. Nelson JB, Greenspan SL, Resnick NM et al. Once weekly oral alendronate prevents bone loss in men on androgen deprivation therapy for prostate cancer. Presented at the 2006 ASCO Prostate Cancer Symposium, San Francisco, CA, February 24-26, 2006.
64. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.